Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation
暂无分享,去创建一个
[1] A. Ghezzi,et al. Dramatic rebounds of MS during pregnancy following fingolimod withdrawal , 2017, Neurology: Neuroimmunology & Neuroinflammation.
[2] E. Waubant,et al. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. , 2016, JAMA neurology.
[3] R. Siripurapu,et al. Severe tumefactive rebound of multiple sclerosis following fingolimod cessation , 2016, BMJ Case Reports.
[4] C. Tan. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2016, Neurology.
[5] A. Lapucci,et al. Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound , 2015, Brain, Behavior, and Immunity.
[6] R. Gold,et al. Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment , 2015, Therapeutic advances in neurological disorders.
[7] Niklas Luetzen,et al. Severe disease reactivation in four patients with relapsing–remitting multiple sclerosis after fingolimod cessation , 2015, Journal of Neuroimmunology.
[8] I. Lotan,et al. Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy , 2014, Journal of the Neurological Sciences.
[9] J. Newcombe,et al. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide , 2014, Annals of neurology.
[10] M. Amato,et al. Withdrawal of fingolimod treatment for relapsing–remitting multiple sclerosis: report of six cases , 2012, Multiple sclerosis.
[11] R. Hohlfeld,et al. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. , 2012, Archives of neurology.
[12] W. Brück,et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis , 2008, Brain : a journal of neurology.